ARTICLE | Management Tracks
CMO Parsey to leave Gilead
Plus: Bodmer to lead Nucleome as CEO and updates from Nouscom, Oxford Biomedica and Aslan
July 18, 2024 12:52 AM UTC
Gilead Sciences Inc. (NASDAQ:GILD) announced the forthcoming departure of CMO Merdad Parsey, who will leave the company early in 2025. Parsey joined the company in 2019, contributing to the growth of its oncology pipeline and more than doubling the company’s portfolio. Parsey discussed his pipeline rationale, biotech challenges and where step changes might come as a guest on The BioCentury Show last year. Gilead is searching for a successor.
Nucleome Therapeutics Ltd. named Mark Bodmer CEO, effective July 24. Bodmer was CSO and president of R&D of Evelo Biosciences Inc. (NASDAQ:EVLO). Nucleome is identifying how disease-associated variants in non-coding DNA cause functional and druggable changes in specific cell types...